Triumvira Immunologics
Triumvira Immunologics: Pioneering safer, more effective T cell therapies for cancer and other diseases since 2015.
Founded
2015Triumvira Immunologics: Pioneering safer, more effective T cell therapies for cancer and other diseases since 2015.
Triumvira Immunologics, founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., is dedicated to developing innovative T cell therapies that are safer and more effective than existing cancer treatments. The company’s core mission is to harness the body’s natural defenses to combat life-threatening cancers. Triumvira's proprietary T cell Antigen Coupler (TAC) technology enhances the immune response by leveraging a T cell’s own recognition, activation, and signaling properties, aiming to treat difficult-to-treat tumors.
Notable figures associated with Triumvira include co-founder Dr. Jonathan Bramson, a prominent figure in immunotherapy research. The company has attracted significant investment from leading biotech investors and has achieved key milestones in preclinical and clinical development stages. Triumvira's impact lies in its potential to revolutionize cancer treatment by providing more effective and safer therapeutic options, thereby improving outcomes for millions of patients worldwide.
Companies similar to Triumvira Immunologics include Trio Pharmaceuticals, Tactiva Therapeutics, 3T Biosciences and Tizona Therapeutics.
Triumvira Immunologics was founded in 2015.
Triumvira Immunologics' headquarters is located in Austin, TX, US.
Triumvira Immunologics' most recent funding round was for $45M (USD) in March 2022.
As of Mar 17, 2022, Triumvira Immunologics has disclosed funding of $100M (USD). Undisclosed round amounts are excluded.
Triumvira Immunologics has 75 employees as of Feb 5, 2024.
Tizona Therapeutics
tizonatx.com
